# PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial

> **NCT04814043** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 57 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** PD-1 inhibitor

## Key facts

- **NCT ID:** NCT04814043
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-20
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2021-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04814043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04814043, "PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04814043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*